Niche capabilities ImmunoChemistry Technologies, LLC offers specialized cell viability, apoptosis, ELISA and immunoassay reagents and services, backed by ISO 13485 certification, presenting a strong value proposition for biotech researchers requiring compliant, high-quality assay components and customization.

Strategic fit As part of the Antibodies Inc. family, ICT can leverage integrated workflows from antibody discovery to functional assays, enabling cross-sell opportunities to customers seeking end-to-end research solutions and broader reagent ecosystems.

Expansion upside Recent and upcoming Antibodies Inc. product launches and acquisitions (Bioporto antibodies, Guinea Pig Chimeric antibodies, Biosensis integration) signal a growing catalog that ICT can align with for joint marketing, bundled kits, and co-branded offerings.

Growth-ready audience With a lean team yet affiliation to a larger life sciences group and a revenue range of one to ten million, ICT should target mid-to-late-stage labs and CROs seeking reliable, customizable assays and outsourcing services to accelerate research timelines.

Procurement leverage ICT’s ISO 13485 facility and custom services for assay development, conjugation, and purification position it to win RFPs and procurement tenders from institutions requiring validated, compliant reagents and tailored solutions for viability, apoptosis, and immunoassays.